Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity
Author: Wardill, H.
Bowen, J.
Al-Dasooqi, N.
Sultani, M.
Bateman, E.
Stansborough, R.
Shirren, J.
Gibson, R.
Citation: Cancer Biology and Therapy, 2014; 15(2):236-244
Publisher: Taylor and Francis
Issue Date: 2014
ISSN: 1538-4047
Statement of
Hannah R Wardill, Joanne M Bowen, Noor Al-Dasooqi, Masooma Sultani, Emma Bateman, Romany Stansborough, Joseph Shirren, and Rachel J Gibson
Abstract: Chemotherapy for cancer causes significant gut toxicity, leading to severe clinical manifestations and an increased economic burden. Despite much research, many of the underlying mechanisms remain poorly understood hindering effective treatment options. Recently there has been renewed interest in the role tight junctions play in the pathogenesis of chemotherapy-induced gut toxicity. To delineate the underlying mechanisms of chemotherapy-induced gut toxicity, this study aimed to quantify the molecular changes in key tight junction proteins, ZO-1, claudin-1, and occludin, using a well-established preclinical model of gut toxicity. Female tumor-bearing dark agouti rats received irinotecan or vehicle control and were assessed for validated parameters of gut toxicity including diarrhea and weight loss. Rats were killed at 6, 24, 48, 72, 96, and 120 h post-chemotherapy. Tight junction protein and mRNA expression in the small and large intestines were assessed using semi-quantitative immunohistochemistry and RT-PCR. Significant changes in protein expression of tight junction proteins were seen in both the jejunum and colon, correlating with key histological changes and clinical features. mRNA levels of claudin-1 were significantly decreased early after irinotecan in the small and large intestines. ZO-1 and occludin mRNA levels remained stable across the time-course of gut toxicity. Findings strongly suggest irinotecan causes tight junction defects which lead to mucosal barrier dysfunction and the development of diarrhea. Detailed research is now warranted to investigate posttranslational regulation of tight junction proteins to delineate the underlying pathophysiology of gut toxicity and identify future therapeutic targets.
Keywords: Animals
Intestinal Mucosa
Intestine, Large
Intestine, Small
Antineoplastic Agents, Phytogenic
Tight Junctions
Zonula Occludens-1 Protein
Rights: ©2014 Landes Bioscience.
DOI: 10.4161/cbt.27222
Appears in Collections:Aurora harvest 2
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.